The cyclin-dependent kinase inhibitor p27kip1 is required for transplantation tolerance induced by costimulatory blockade

Journal of Immunology

Volumn 177, Issue 8, 2006, Pages 5169-5176

  Rowell, Emily A ^a   Wang, Liqing ^b   Hancock, Wayne W ^a,b   Wells, Andrew D ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CLONAL ANERGY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

EID: 33749521081     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.8.5169     Document Type: Article

References (58)

1. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258.
2. Morgan, D. O. 1995. Principles of CDK regulation. Nature 374: 131-134.
3. Vidal, A., and A. Koff. 2000. Cell-cycle inhibitors: three families united by a common cause. Gene 247: 1-15.
4. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573.
5. 0 T cells. J. Immunol. 158: 5642-5648.
6. Kip1 regulates T cell proliferation. J. Biol. Chem. 276: 21976-21983.
7. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
8. 1a phase of the cell cycle. J. Immunol. 151: 1245-1254.
9. Beverly, B., S. M. Kang, M. J. Lenardo, and R. H. Schwartz. 1992. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 4: 661-671.
10. Kip1. J. Immunol. 166: 952-958.
11. Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell effector function and anergy avoidance are quantitatively linked to cell division. J. Immunol. 165: 24321-2443.
12. kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 6: 290-297.
13. Powell, J. D., C. G. Lerner, and R. H. Schwartz. 1999. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162: 2775-2784.
14. Kip1 expression is required for development and function of T cells. J. Immunol. 166: 304-312.
15. + T cell proliferation and effector function. J. Immunol. 174: 3359-3368.
16. Kip1-deficient mice. Cell 85: 733-744.
17. Corry, R. J., H. S. Winn, and P. S. Russell. 1973. Primarily vascularized allografts of hearts in mice. Transplantation 16: 343-350.
18. Stewart, S., G. L. Winters, M. C. Fishbein, H. D. Tazelaar, J. Kobashigawa, J. Abrams, C. B. Andersen, A. Angelini, G. J. Berry, M. M. Burke, et al. 2005. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24: 1710-1720.
19. + T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J. Exp. Med. 201: 1037-1044.
20. Lehr, H. A., D. A. Mankoff, D. Corwin, G. Santeusanio, and A. M. Gown. 1997. Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J. Histochem. Cytochem. 45: 1559-1565.
21. Suchin, E. J., P. B. Langmuir, E. Palmer, M. H. Sayegh, A. D. Wells, and L. A. Turka. 2001. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166: 973-981.
22. Hancock, W. W., M. H. Sayegh, X. G. Zheng, R. Peach, P. S. Linsley, and L. A. Turka. 1996. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 93: 13967-13972.
23. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381: 434-438.
24. + T lymphocytes. J. Immunol. 174: 2481-2484.
25. Kip1. J. Immunol. 165: 6270-6277.
26. Li, Y., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, and T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5: 1298-1302.
27. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
28. Bird, J. J., D. R. Brown, A. C. Mullen, N. H. Moskowitz, M. A. Mahowald, J. R. Sider, T. F. Gajewski, C. R. Wang, and S. L. Reiner. 1998. Helper T cell differentiation is controlled by the cell cycle. Immunity 9: 229-237.
29. Gett, A. V., and P. D. Hodgkin. 1998. Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation. Proc. Natl. Acad. Sci. USA 95: 9488-9493.
30. Gudmundsdottir, H., A. D. Wells, and L. A. Turka. 1999. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J. Immunol. 162: 5212-5223.
31. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11:492-503.
32. Wood, K. J., and S. Sakaguchi. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3: 199-210.
33. Kip1-dependent mechanism. J. Clin. Invest. 114: 419-426.
34. Li, X. C., T. B. Strom, L. A. Turka, and A. D. Wells. 2001. T cell death and transplantation tolerance. Immunity 14: 407-416.
35. Appleman, L. J., A. Berezovskaya, I. Grass, and V. A. Boussiotis. 2000. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J. Immunol. 164: 144-151.
36. kip1 expression in human peripheral T lymphocytes. Eur. J. Immunol. 29: 789-798.
37. 1 and S phase. Nature 413: 323-327.
38. Avni, O., and A. Rao. 2000. T cell differentiation: a mechanistic view. Curr. Opin. Immunol. 12: 654-659.
39. Fitzpatrick, D. R., and C. B. Wilson. 2003. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin. Immunol. 109: 37-45.
40. Reiner, S. L. 2005. Epigenetic control in the immune response. Hum. Mol. Genet. 14(Spec. No. 1): R41-R46.
41. Wells, A. D., M. C. Walsh, J. A. Bluestone, and L. A. Turka. 2001. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 108: 895-903.
42. kip1 degradation. J. Immunol. 169: 4723-4731.
43. + T cells. Immunology 107: 480-488.
44. 1/S transition. Cancer Surv. 29: 7-23.
45. Coverley, D., H. Laman, and R. A. Laskey. 2002. Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat. Cell Biol. 4: 523-528.
46. 2/M events by Cdc25 A through phosphorylation-dependent modulation of its stability. EMBO J. 21: 5911-5920.
47. Koff, A., F. Cross, A. Fisher, J. Schumacher, K. Leguellec, M. Philippe, and J. M. Roberts. 1991. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217-1228.
48. Swank, R. A., J. P. Th'ng, X. W. Guo, J. Valdez, E. M. Bradbury, and L. R. Gurley. 1997. Four distinct cyclin-dependent kinases phosphorylate histone H1 at all of its growth-related phosphorylation sites. Biochemistry 36: 13761-13768.
49. Moroy, T., and C. Geisen. 2004. Cyclin E. Int. J. Biochem. Cell Biol. 36: 1424-1439.
50. 1 cyclin-dependent kinases. Nature 376: 88-91.
51. Matsuura, I., N. G. Denissova, G. Wang, D. He, J. Long, and F. Liu. 2004. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430: 226-231.
52. Perkins, N. D., L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, and G. J. Nabel. 1997. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275: 523-527.
53. 1/S phase. Biochem. Biophys. Res. Commun. 249: 728-734.
54. Wolff, B., and M. Naumann. 1999. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-κB. Oncogene 18: 2663-2666.
55. Li, J., S. H. Joo, and M. D. Tsai. 2003. An NF-κB-specific inhibitor, IκBα, binds to and inhibits cyclin-dependent kinase 4. Biochemistry 42: 13476-13483.
56. Tzachanis, D., G. J. Freeman, N. Hirano, A. A. van Puijenbroek, M. W. Delfs, A. Berezovskaya, L. M. Nadler, and V. A. Boussiotis. 2001. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat. Immunol. 2: 1174-1182.
57. Kontgen, F., R. J. Grumont, A. Strasser, D. Metcalf, R. Li, D. Tarlinton, and S. Gerondakis. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9: 1965-1977.
58. Butscher, W. G., C. M. Haggerty, S. Chaudhry, and K. Gardner. 2001. Targeting of p300 to the interleukin-2 promoter via CREB-Rel cross-talk during mitogen and oncogenic molecular signaling in activated T-cells. J. Biol. Chem. 276: 27647-27656.